Could Cannabis Help Prevent Alzheimer's? Unless Lawmakers Adapt To Allow Its Study, We May Never Know

Medical cannabis is becoming more and more common around the US, with over 60% of states having some form of medical marijuana law in effect. In addition, 8 states have legalized marijuana for recreational use.

Public opinion has swung in favor of decriminalizing marijuana – and regardless of your opinion on recreational use, there are many studies that show medical marijuana has a wide variety of beneficial effects.

Yet, many scientists are still being blocked at a federal level from conducting wide-scale studies on the effects of medical cannabis on conditions like cancer, chronic pain, and even Alzheimer's and dementia.

Researchers at the Salk Institute in California – where medical and recreational marijuana are legal – were blocked by the DEA from obtaining clearance to test a marijuana extract on mice, in an effort to study the effects of the drug on amyloid deposits.

Amyloid deposits are currently thought to be the primary cause of Alzheimer’s and dementia. This toxic “plaque” builds up around the brain’s neurons, reducing their functionality, and eventually leading to neurological death.

Read more of this article? Click Here

5 Eating Habits That Could Help Reduce The Risk Of Alzheimer’s

Could avoiding Alzheimer’s be as simple as changing your diet? We’re still not certain about the precise cause of Alzheimer’s, but there are quite a few studies that have been done showing that lifestyle choices like exercise habits, sleeping schedules, and even dietary habits can contribute to a higher risk of Alzheimer’s.

High blood sugar, in particular, is associated with increased strain on the brain and cardiovascular system – and may be one of the major lifestyle-related risk factors of the disease.

Let’s take a look at 5 eating habits that could help you reduce your risk of developing Alzheimer’s and dementia, according to Dr. Marilyn Glenville, a leading nutritionist.

Pharmaceutical Company Neurotrope To Release Results Of  Phase II Trials Of New Alzheimer’s Therapy Drug Bryostatin

The quest to find a true cure for Alzheimer’s has taken another step forward. 

Neurotrope, a leading pharmaceutical company, has announced that they will be releasing the results from their latest phase II trial of Bryostatin, their experimental Alzheimer’s therapy drug.

This current set of trials began in January 2016, when 148 moderate-to-severe Alzheimer’s patients were dosed at 26 different test sites all across the US.